Stem Cell Retroviral Gene Therapy Trials May Proceed On Case-By-Case Basis
Executive Summary
The 27 hematopoietic stem cell trials in the U.S. that use retroviral vectors should be allowed to proceed on a case-by-case basis based on risk/benefit profiles, FDA's Biologics Response Modifiers Advisory Committee agreed at its Feb. 28 meeting
You may also be interested in...
Gene Therapy Trial Clinical Hold Will Be Topic Of FDA, NIH Meetings
FDA's Biological Response Modifiers Advisory Committee and NIH's Recombinant DNA Advisory Committee will each discuss the latest adverse event to occur in a French gene transfer trial at upcoming meetings
SCID Event Should Be Included In All Retroviral Therapy Informed Consent
All retroviral gene therapy trial informed consent forms should include information about a leukemia-like event that occurred in a recent severe combined immunodeficiency gene therapy trial, FDA's Biological Response Modifiers Advisory Committee recommended Oct. 10
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011